3,610 Shares in Danaher Co. (NYSE:DHR) Acquired by Elevate Capital Advisors LLC

Elevate Capital Advisors LLC acquired a new stake in Danaher Co. (NYSE:DHR) during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 3,610 shares of the conglomerate’s stock, valued at approximately $829,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in DHR. Heck Capital Advisors LLC purchased a new stake in shares of Danaher during the fourth quarter worth $27,000. Decker Retirement Planning Inc. acquired a new stake in shares of Danaher during the 4th quarter valued at about $31,000. Golden State Wealth Management LLC bought a new stake in shares of Danaher in the 4th quarter valued at approximately $31,000. Strategic Financial Concepts LLC acquired a new position in Danaher in the fourth quarter worth approximately $31,000. Finally, Teachers Insurance & Annuity Association of America bought a new position in Danaher during the third quarter valued at approximately $39,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Insider Activity

In related news, SVP Brian W. Ellis sold 5,700 shares of the business’s stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $224.13, for a total value of $1,277,541.00. Following the sale, the senior vice president now owns 20,230 shares of the company’s stock, valued at $4,534,149.90. The trade was a 21.98 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 11.10% of the company’s stock.

Danaher Price Performance

Shares of NYSE:DHR opened at $206.92 on Monday. The firm has a market capitalization of $149.45 billion, a PE ratio of 39.19, a PEG ratio of 2.68 and a beta of 0.83. The company has a current ratio of 1.40, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31. Danaher Co. has a 1-year low of $205.79 and a 1-year high of $281.70. The business’s 50 day moving average is $232.72 and its 200-day moving average is $251.70.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share (EPS) for the quarter, meeting the consensus estimate of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same period last year, the firm posted $2.09 EPS. Sell-side analysts predict that Danaher Co. will post 7.67 earnings per share for the current year.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Friday, December 27th were paid a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a yield of 0.52%. The ex-dividend date was Friday, December 27th. Danaher’s dividend payout ratio is 20.45%.

Analyst Upgrades and Downgrades

Several analysts have commented on DHR shares. Wolfe Research raised shares of Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 target price for the company in a research report on Thursday, October 31st. Barclays cut their target price on Danaher from $275.00 to $240.00 and set an “equal weight” rating on the stock in a report on Thursday, January 30th. Guggenheim assumed coverage on Danaher in a research note on Thursday, December 19th. They set a “buy” rating and a $275.00 price target for the company. Bank of America raised Danaher from a “neutral” rating to a “buy” rating and set a $290.00 price objective on the stock in a research note on Friday, December 13th. Finally, JPMorgan Chase & Co. decreased their target price on Danaher from $310.00 to $300.00 and set an “overweight” rating for the company in a research report on Tuesday, January 28th. Seven investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat.com, Danaher has an average rating of “Moderate Buy” and a consensus target price of $278.00.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.